Abstract
Introduction Currently, dendritic cells (DC) are tested as vectors for cancer immunotherapy. However, little is known about the mechanisms regulating DC migration. Sphingosinekinase (SphK) and its catalytic product Sphingosine-1phosphate (S1P) play a central role in processes such as cellular differentiation, survival and migration, which are often disregulated in cancer. Here, we examined the role of SphK and S1P in migration of DC.
Highlights
Dendritic cells (DC) are tested as vectors for cancer immunotherapy
Our results suggest a role for SphK/S1P in accumulation of peripheral iDC at sites of antigen invasion
These findings could provide a new approach to optimise dendritic cells (DC)-based cancer immunotherapy by therapeutic modulation of SphK/S1P and have to be verified in an animal model in the step
Summary
Dendritic cells (DC) are tested as vectors for cancer immunotherapy. Little is known about the mechanisms regulating DC migration. Sphingosinekinase (SphK) and its catalytic product Sphingosine-1phosphate (S1P) play a central role in processes such as cellular differentiation, survival and migration, which are often disregulated in cancer. We examined the role of SphK and S1P in migration of DC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
